uniQure N.V. (NASDAQ:QURE) Stock Rated “Moderate Buy” by Sell-Side Analysts

uniQure N.V. (NASDAQ:QURE) has received a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $58.18.

A number of equities analysts have recently weighed in on QURE shares. Mizuho increased their target price on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research note on Wednesday, June 17th. Royal Bank Of Canada upped their price objective on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Leerink Partners increased their price objective on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Finally, Barclays dropped their target price on uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, July 30th.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new position in shares of uniQure during the 2nd quarter worth approximately $15,254. IFP Advisors Inc acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. Stephens Inc. AR acquired a new stake in shares of uniQure in the first quarter valued at approximately $182,000. Cannon Global Investment Management LLC bought a new stake in shares of uniQure in the first quarter valued at approximately $199,000. Finally, Rangeley Capital LLC boosted its stake in shares of uniQure by 52.9% in the first quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 4,500 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported that the 36-month analysis in 15 high-dose patients showed an 80% slowing of disease progression on cUHDRS and a 67% slowing on Total Functional Capacity (TFC). The FDA has indicated that 36-month data can serve as the primary basis for the company’s accelerated-approval application, supporting management’s view that the regulatory path remains intact. uniQure AMT-130 data release
• Positive Sentiment: At 48 months, TFC showed a 61% slowing of functional decline, and the company said dose-dependent results and a post-hoc analysis using an earlier external control continued to support AMT-130’s potential clinical benefit. Some analysts characterized the selloff as excessive and maintained a speculative bullish view. uniQure price target analysis
• Neutral Sentiment: Despite the sharp decline, published analyst targets remain well above the current trading level, reflecting substantial potential upside if AMT-130 ultimately gains approval. Those targets are highly dependent on regulatory acceptance and confirmation of efficacy in later-stage testing.
• Negative Sentiment: The key 48-month cUHDRS endpoint showed only 44% slowing and did not reach statistical significance (p=0.144). Investors viewed the weaker four-year result, compared with the stronger 36-month data, as evidence that treatment benefits may be less durable than previously expected. Missing data and possible survivor bias in the external control group further complicate interpretation. Reuters report on AMT-130 trial data
• Negative Sentiment: Several law firms have announced investigations into potential securities-law violations or misleading disclosures related to uniQure’s clinical data. These announcements do not establish wrongdoing, but they add reputational and litigation risk. Kirby McInerney uniQure investigation

uniQure Stock Down 1.4%

uniQure stock opened at $24.16 on Friday. The stock has a market cap of $1.68 billion, a P/E ratio of -6.02 and a beta of 0.94. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure has a twelve month low of $8.73 and a twelve month high of $71.50. The company’s 50-day moving average price is $43.93 and its two-hundred day moving average price is $33.35.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter last year, the business earned ($0.69) earnings per share. As a group, analysts expect that uniQure will post -3.82 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.